Cargando…
Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins
T-cell acute lymphoblastic leukemias (T-ALL) represent 15% of pediatric and 25% of adult ALL. Since they have a particularly poor outcome in relapsed/refractory cases, identifying prognosis factors at diagnosis is crucial to adapting treatment for high-risk patients. Unlike acute myeloid leukemia an...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791998/ https://www.ncbi.nlm.nih.gov/pubmed/35082269 http://dx.doi.org/10.1038/s41408-022-00613-9 |
_version_ | 1784640310580609024 |
---|---|
author | Steimlé, Thomas Dourthe, Marie-Emilie Alcantara, Marion Touzart, Aurore Simonin, Mathieu Mondesir, Johanna Lhermitte, Ludovic Bond, Jonathan Graux, Carlos Grardel, Nathalie Cayuela, Jean-Michel Arnoux, Isabelle Gandemer, Virginie Balsat, Marie Vey, Norbert Macintyre, Elizabeth Ifrah, Norbert Dombret, Hervé Petit, Arnaud Baruchel, André Ruminy, Philippe Boissel, Nicolas Asnafi, Vahid |
author_facet | Steimlé, Thomas Dourthe, Marie-Emilie Alcantara, Marion Touzart, Aurore Simonin, Mathieu Mondesir, Johanna Lhermitte, Ludovic Bond, Jonathan Graux, Carlos Grardel, Nathalie Cayuela, Jean-Michel Arnoux, Isabelle Gandemer, Virginie Balsat, Marie Vey, Norbert Macintyre, Elizabeth Ifrah, Norbert Dombret, Hervé Petit, Arnaud Baruchel, André Ruminy, Philippe Boissel, Nicolas Asnafi, Vahid |
author_sort | Steimlé, Thomas |
collection | PubMed |
description | T-cell acute lymphoblastic leukemias (T-ALL) represent 15% of pediatric and 25% of adult ALL. Since they have a particularly poor outcome in relapsed/refractory cases, identifying prognosis factors at diagnosis is crucial to adapting treatment for high-risk patients. Unlike acute myeloid leukemia and BCP ALL, chromosomal rearrangements leading to chimeric fusion-proteins with strong prognosis impact are sparsely reported in T-ALL. To address this issue an RT-MPLA assay was applied to a consecutive series of 522 adult and pediatric T-ALLs and identified a fusion transcript in 20% of cases. PICALM-MLLT10 (4%, n = 23), NUP214-ABL1 (3%, n = 19) and SET-NUP214 (3%, n = 18) were the most frequent. The clinico-biological characteristics linked to fusion transcripts in a subset of 235 patients (138 adults in the GRAALL2003/05 trials and 97 children from the FRALLE2000 trial) were analyzed to identify their prognosis impact. Patients with HOXA trans-deregulated T-ALLs with MLLT10, KMT2A and SET fusion transcripts (17%, 39/235) had a worse prognosis with a 5-year EFS of 35.7% vs 63.7% (HR = 1.63; p = 0.04) and a trend for a higher cumulative incidence of relapse (5-year CIR = 45.7% vs 25.2%, HR = 1.6; p = 0.11). Fusion transcripts status in T-ALL can be robustly identified by RT-MLPA, facilitating risk adapted treatment strategies for high-risk patients. |
format | Online Article Text |
id | pubmed-8791998 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-87919982022-02-07 Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins Steimlé, Thomas Dourthe, Marie-Emilie Alcantara, Marion Touzart, Aurore Simonin, Mathieu Mondesir, Johanna Lhermitte, Ludovic Bond, Jonathan Graux, Carlos Grardel, Nathalie Cayuela, Jean-Michel Arnoux, Isabelle Gandemer, Virginie Balsat, Marie Vey, Norbert Macintyre, Elizabeth Ifrah, Norbert Dombret, Hervé Petit, Arnaud Baruchel, André Ruminy, Philippe Boissel, Nicolas Asnafi, Vahid Blood Cancer J Article T-cell acute lymphoblastic leukemias (T-ALL) represent 15% of pediatric and 25% of adult ALL. Since they have a particularly poor outcome in relapsed/refractory cases, identifying prognosis factors at diagnosis is crucial to adapting treatment for high-risk patients. Unlike acute myeloid leukemia and BCP ALL, chromosomal rearrangements leading to chimeric fusion-proteins with strong prognosis impact are sparsely reported in T-ALL. To address this issue an RT-MPLA assay was applied to a consecutive series of 522 adult and pediatric T-ALLs and identified a fusion transcript in 20% of cases. PICALM-MLLT10 (4%, n = 23), NUP214-ABL1 (3%, n = 19) and SET-NUP214 (3%, n = 18) were the most frequent. The clinico-biological characteristics linked to fusion transcripts in a subset of 235 patients (138 adults in the GRAALL2003/05 trials and 97 children from the FRALLE2000 trial) were analyzed to identify their prognosis impact. Patients with HOXA trans-deregulated T-ALLs with MLLT10, KMT2A and SET fusion transcripts (17%, 39/235) had a worse prognosis with a 5-year EFS of 35.7% vs 63.7% (HR = 1.63; p = 0.04) and a trend for a higher cumulative incidence of relapse (5-year CIR = 45.7% vs 25.2%, HR = 1.6; p = 0.11). Fusion transcripts status in T-ALL can be robustly identified by RT-MLPA, facilitating risk adapted treatment strategies for high-risk patients. Nature Publishing Group UK 2022-01-26 /pmc/articles/PMC8791998/ /pubmed/35082269 http://dx.doi.org/10.1038/s41408-022-00613-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Steimlé, Thomas Dourthe, Marie-Emilie Alcantara, Marion Touzart, Aurore Simonin, Mathieu Mondesir, Johanna Lhermitte, Ludovic Bond, Jonathan Graux, Carlos Grardel, Nathalie Cayuela, Jean-Michel Arnoux, Isabelle Gandemer, Virginie Balsat, Marie Vey, Norbert Macintyre, Elizabeth Ifrah, Norbert Dombret, Hervé Petit, Arnaud Baruchel, André Ruminy, Philippe Boissel, Nicolas Asnafi, Vahid Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins |
title | Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins |
title_full | Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins |
title_fullStr | Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins |
title_full_unstemmed | Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins |
title_short | Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins |
title_sort | clinico-biological features of t-cell acute lymphoblastic leukemia with fusion proteins |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791998/ https://www.ncbi.nlm.nih.gov/pubmed/35082269 http://dx.doi.org/10.1038/s41408-022-00613-9 |
work_keys_str_mv | AT steimlethomas clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT dourthemarieemilie clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT alcantaramarion clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT touzartaurore clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT simoninmathieu clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT mondesirjohanna clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT lhermitteludovic clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT bondjonathan clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT grauxcarlos clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT grardelnathalie clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT cayuelajeanmichel clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT arnouxisabelle clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT gandemervirginie clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT balsatmarie clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT veynorbert clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT macintyreelizabeth clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT ifrahnorbert clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT dombretherve clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT petitarnaud clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT baruchelandre clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT ruminyphilippe clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT boisselnicolas clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins AT asnafivahid clinicobiologicalfeaturesoftcellacutelymphoblasticleukemiawithfusionproteins |